Daxor files 510(k) for injection syringe:
This article was originally published in Clinica
Executive Summary
Daxor has filed a 510(k) submission with the US FDA for a quantitative syringe kit for use with its BVA-100 blood volume analyser. The syringe is designed to deliver more than 99.9% of its content in diagnostic studies in which a precise and complete injection is required. Daxor, based in New York, has been awaiting clearance for its BVA-100 system since November last year.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.